Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986253 With Nivolumab ± Ipilimumab in Advanced Cancers
2023-509061-20-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, open-label trial of adakitug in Nonhematologic neoplasms (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety: Number and severity of side effects and Efficacy: Tumor response by formal criteria. Started Nov 2018; status: completed.
02
Drugs
adakitug
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-509061-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509061-20-00.